Physician profile
Daniel T Laich
NPI 1558357046
$8,805.46
in general payments reported to CMS, 2019-2025
40 companies · $388 in 2025
The $388 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $4,055 · 2021: $859 · 2022: $820 · 2023: $451 · 2024: $737 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $2,082.38 | 2019-2020 | |
| Medical Device Business Services, INC. | $1,897.87 | 2020-2023 | Teligen |
| Medtronic USA, INC. | $1,474.25 | 2020 | |
| Depuy Synthes Sales INC. | $437.50 | 2020-2025 | Fibergraft Aeridyan Matrix, Viper, Teligen |
| Biogen, INC. | $359.59 | 2020-2025 | Vumerity, Tysabri |
| Arthrex, INC. | $290.59 | 2023-2024 | |
| Carlsmed, INC. | $252.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $150.60 | 2021-2025 | Ultomiris, Soliris |
| Adcura, INC. | $145.00 | 2022 | |
| Trackx Technology, INC. | $144.05 | 2022 | |
| Neurocrine Biosciences, INC. | $139.76 | 2022-2024 | Ingrezza, Ongentys |
| Orthofix Medical, INC. | $138.31 | 2024-2025 | Cervical-Stim, Spinal-Stim, Stim On Track |
| Janssen Pharmaceuticals, INC | $117.14 | 2021-2022 | |
| Acorda Therapeutics, INC | $92.86 | 2019-2024 | Ampyra, Inbrija |
| Centinel Spine, LLC | $89.10 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $82.46 | 2021-2024 | Nuplazid |
| Abbvie INC. | $80.45 | 2023-2025 | |
| Mdd US Operations, LLC | $73.54 | 2021-2024 | Gocovri, Gocovri |
| Ucb, INC. | $66.30 | 2019-2024 | Rystiggo, Briviact |
| Lilly USA, LLC | $63.84 | 2020-2023 | Emgality, Reyvow |
| Sk Life Science, INC. | $62.40 | 2020-2021 | |
| Banner Life Sciences, LLC | $61.87 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $51.65 | 2019-2020 | |
| Lundbeck LLC | $45.61 | 2021-2024 | Vyepti |
| Integrity Implants INC. | $44.42 | 2019 | |
| Allergan, INC. | $37.63 | 2019-2020 | |
| Emd Serono, INC. | $35.89 | 2023 | Mavenclad |
| Si-Bone, INC. | $34.69 | 2020 | |
| Eisai INC. | $33.97 | 2019-2022 | |
| Genentech USA, INC. | $33.03 | 2019-2020 | |
| Hospira, INC. | $31.46 | 2019 | |
| Aesculap Implant Systems, LLC | $31.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.38 | 2025 | |
| Grifols USA, LLC | $20.79 | 2023 | Gamunex-C |
| Livanova USA, INC. | $19.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.86 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.25 | 2019 | |
| Tanabe Pharma America, INC. | $14.00 | 2019 | |
| Stryker Corporation | $13.84 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$888.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Laich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.